Your patient has been systematically titrating his basal insulin dose for the last 6 months. His daily dose is NPH .90 U/kg/day. Despite his good efforts, you decide it would be prudent to add a prandial insulin dose to his treatment regimen. Which of the following scenarios might lead you to this conclusion?

A. A1C=7.4%, FPG less than 130 mg/dl, PPG greater than 180 mg/dl
B. A1C=7.0%, FPG less than 130 mg/dl, PPG less than 180 mg/dl
C. A1C=7.0%, FPG less than 120mg/dl, PPG less than 160mg/dl
D. A1C=6.8%, FPG less than 120 mg/dl, PPG less than 160 mg/dl

Follow the link for the answer.

Lowest-priced insulin required to safely, effectively achieve treatment goals should be prescribed

These patients are tightly controlled with glucose-lowering medications with high risk of hypoglycemia

Diagnostic thresholds should be adapted using local populations, authors say

Dual users had the highest prevalence of respiratory symptoms

Full-nut dose lowered HbA1c, estimated cholesterol levels in LDL particles with diameter <255 ångströms

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for July 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Learning to …

This week it is all about insulin, and for a good reason. Although we have some great oral and non-insulin injectables for the treatment of type 2 Diabetes, and many of these can be used with our type 1 patients, the fact remains that if you have type 1 diabetes …

This summer I had the opportunity as a student pharmacist to attend a camp for youth with type 1 diabetes (T1D) and assist as a member of the medical staff. We spent the first few days setting up, going over camp procedures and policies, and preparing for arrival of the campers. This was my first time helping at such an event, and my expectations of how deeply the camp experience would impact the lives of the campers (and myself included!) were greatly exceeded.

Kittie Wyne, MD, PhD, FACE, FNLA is an endocrinologist specializing in the management of diabetes, lipids and hypertension. She has recently moved to The Ohio State University where she is the Director of the OSU Adult Type 1 Diabetes Program. Dr. Wyne earned her medical degree from the Pritzker School of Medicine at the University of Chicago.